Watson Laboratories Inc., Alkem Laboratories, Amerigen Pharmaceuticals Ltd., Forest Laboratories, Glenmark, Hetero Drugs, Indchemie Health Specialties Pvt. Ltd.

Forest and Johnson & Johnson's Janssen Pharmaceutica N.V. unit filed suit against Amerigen, Glenmark, Hetero Drugs, Torrent and Watson in the U.S. District Court for the District of Delaware claiming ANDAs for generic versions of hypertension drug Bystolic nebivolol infringe U.S. Patent No. 6,545,040. The patent covers methods of treating hypertension with Bystolic and expires in December 2021. Forest and Janssen also filed suit in the U.S. District Court for the Northern District of Illinois against Alkem and Indchemie claiming ANDAs from the two companies also infringe the patent. Forest said the ANDAs contain Paragraph IV certifications that the patent is invalid, unenforceable and/or will not be infringed by the generic. ...